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Abstract 
Background  Ciliopathies are a group of diseases associated with abnormal structure or function of primary cilia. Ciliopathies include 
polycystic kidney disease (PKD), a pathology associated with vascular hypertension. We previously showed that cilia length regulates cilia 
function, and cilia function is required for nitric oxide (NO) biosynthesis in endothelial cells. Because patients with PKD show abnormal 
sensory cilia function, the aim of our current study was to search for a targeted therapy focused on primary cilia, which we refer to as ‘cilio-
therapy’. Methods and Results  In the present studies, our in vitro analyses refined fenoldopam as an equipotent and more specific dopa-
minergic agonist to regulate cilia length and function. Our in vivo studies indicated that fenoldopam increased cilia length and serum NO 
thereby reducing blood pressure in a PKD mouse model. Our crossover, multicenter, double-blind and placebo-controlled clinical study fur-
ther indicated that cilia-targeting therapy showed an overall reduction in mean arterial pressure in PKD patients. Conclusions  Overall, our 
studies provide the first evidence of ciliotherapy as an innovative intervention in patients with abnormal primary cilia. 
J Geriatr Cardiol 2014; 11: 63−73. doi: 10.3969/j.issn.1671-5411.2014.01.001 
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1  Introduction  
Polycystic kidney disease (PKD) is the most common 
life-threatening hereditary genetic disease, compared to the 
combined numbers of individuals affected by cystic fibrosis, 
Downs syndrome, hemophilia, muscular dystrophy, and 
sickle cell anemia. One of the most concerning issues in 
PKD is vascular hypertension. In particular, hypertension 
occurs early in PKD compared to the general population.[1] 
Although it has been known that PKD is caused by dys-
function in mechanosensory primary cilia,[2,3] there is un-
fortunately no targeted therapy on primary cilia at present.  
It has been shown that cilia function can be regulated by 
cilia length.[4] Furthermore, vascular endothelia require 
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proper cilia function for nitric oxide (NO) biosynthesis, in 
which primary cilia act as molecular switches to initiate NO 
biochemical reaction.[5,6] More importantly, vascular endo-
thelia obtained from patients with PKD show abnormal 
sensory cilia function.[5,7] Based on our previous drug 
screening that dopamine enhances cilia function by extend-
ing the length of cilia,[8] the aim of our current study was 
therefore to search for a targeted therapy focused on pri-
mary cilia. 
2  Methods 
The use of animal cells or tissues was approved by the 
Animal Care and Use Committee of The University of 
Toledo. The title of our animal cell protocol was Molecular 
Biology of Kidney Diseases (No. N-105587), and it was 
approved on June 2010. Signed and informed consent to 
participate in our clinical study was obtained from the pa-
tients, and our clinical protocols were approved by the De-
partment for Human Research Protections of the Biomedi-
cal Institutional Review Board of the University of Baghdad, 
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College of Pharmacy. Our clinical protocols were also 
posted publicly and approved by the International Clinical 
Trials Registry Platform of the World Health Organization. 
The clinical trial registry number was IRCT2012110611384N1. 
The title of our clinical protocols was Dopamine Receptor 
in Hypertension with Polycystic Kidney Disease (No. 
DR-PKD), and it was approved on May 2012. The study 
participants were recruited in June 1 of 2012, and the study 
was completed in September 30 of 2012.  
2.1  Cell culture 
Mouse endothelial cells were previously generated and 
characterized in our laboratory.[6] Cells were grown in Dul-
becco’s Modification of Eagle's Media (Cellgro, Inc.) con-
taining 10% fetal bovine serum and 1% penicillin G plus 
streptomycin sulfate (HyClone, Inc.) at 39°C for 3–5 days 
until fully differentiated before analysis. 
2.2  Endothelial-specific Pkd1 mouse model 
Endothelial specific-Cre mice were purchased from 
German Cancer Research Center (DKFZ) in 2009. These 
mice were bred with Pkd1flox/flox, as previously described.[9] 
Only male mice in Balb/C background after backcross of 15 
generations were used to reduce complexity in hormonal 
regulation of blood pressure or genetic background, al-
though female mice shared the same blood pressure as in 
males (data not shown). The endothelial-specific Cre mice 
were confirmed with a ROSA model, purchased from the 
Jackson Laboratory in Maine (Stock Number: 007576). To 
induce Cre recombinant and thus a gene knockout, one- 
week old pups were injected intra-peritoneally with 250 μg 
of 50 μL tamoxifen every day for five consecutive days. 
Blood pressure reading was taken two weeks later. 
2.3  Blood pressure measurement 
After inactivation of Pkd1 in Tie2Cre:Pkd1flox/flox at one- 
week old, blood pressure was taken from three-week old 
mice showing no apparent renal cyst formation. Blood 
pressure was measured in conscious, trained mice at room 
temperature using a non-invasive blood pressure system 
tail-cuff monitor and a built-in photoelectric sensor (Vis-
itech System, NC). Blood pressure measurements were 
taken twice daily for the duration of the study after the ini-
tial three days acclimating each mouse to the cuff. The data 
from the tail cuff method was also verified with a more in-
vasive, surgically implanted telemetry probe (data not 
shown). Per previous literature,[10] our initial dosage of fen-
oldopam was 2 mg/kg per day; we also tried 1 mg/kg which 
provided us with a less consistent result (data not shown). 
The dosage of 1.5 mg/kg per day was finally used as it was 
sufficient to lower the blood pressure consistently in Pkd1 
mice. The 1.5 mg/kg of fenoldopam was slowly adminis-
tered for 20–30 min duration intravenously every day for 
the duration of our study. All measurements were performed 
by two-blinded operators.  
2.4  NO measurement 
A non-fluorescent, CO2-independent medium for imag-
ing was used (pH 7.4). This medium contained (in mmol/L) 
CaCl2 1.26, MgSO4 0.81, KCl 5.4, KH2PO4 0.44, NaCl 137, 
Na2HPO4 0.34, NaHCO3 4.166 and D-glucose 5.6. After 
incubation with the NO-sensitive probe 4-amino-5-methyl- 
amino-2',7'-difluorofluorescein (DAF-FM, 20 μmol/L; Invi-
trogen, Inc.) for 30 min at 39°C, cells were washed to re-
move excess probe. DAF-FM images were captured at ex-
citation and emission wavelengths of 495 and 515 nm every 
5 s through a Nikon TE2000 microscope equipped with a 
Coolsnap EZ cooled charge-coupled device monochrome 
digital camera using Metamorph software (Molecular De-
vices, Corp.). In some cases, serum NO was measured with 
nitrate/nitrite fluoremetric assay kit (Cayman Chemical, 
Corp.) as described previously.[5] 
2.5  Immunofluorescence 
For cilia length studies, endothelial cells were incubated 
with fenoldopam (Hospira, Inc.) at 0, 1.0, 10.0, 20.0 and 
50.0 μmol/L for 16 h at 39°C. Changes in the cilia length in 
the endothelial cells of femoral arteries were also measured 
and compared to age-matched control groups. Cells and 
tissues were fixed as described previously.[8] Anti-acetylated 
α-tubulin antibody (1: 10,000 dilution; clone 6-11B-1; 
Sigma, Inc.), fluorescein isothiocyanate (FITC)-labeled an-
ti-mouse antibody (1: 500 dilution; Vector Lab, Inc.), and 
4′,6-diamidino-2-phenylindol (DAPI, Vector Lab, Inc.) 
were used. All measurements and analyses were performed 
by two-blinded operators.  
2.6  Cilia function analysis 
For fluid-shear stress experiments, cells grown on glass- 
bottom plates were installed in custom-made apparatus 
measured 3 cm × 2.5 mm connected with 2 pumps (Instech, 
Corp.), one pump for inward fluid flow from a reservoir to 
the cells and the other for outward fluid flow from the cells 
to the reservoir, as previously described.[5] For dopamine 
receptor-5 (DR5) agonist experiments, cells were chal-
lenged with dopamine (10 μmol/L; Sigma, Inc.) or fenoldo-
pam (10 μmol/L; Hospira, Inc.). In some experiments, cells 
were incubated with fenoldopam (10 μmol/L) for 16 h at 
39°C before shear stress experiment. 
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2.7  Patient selection criteria 
Signed and informed consent to examine effects of 
levodopa was obtained from the patients, and blood collec-
tion protocols were approved by the Graduate Studies 
Committee of the University of Baghdad, Baghdad, Iraq. 
Inclusion of patients was approved by and consulted with 
the Alkadhumia Academic Hospital and The Renal Diseases 
and Transplant Center at the Medical City Complex, Bagh-
dad. Thus, the settings and locations where the data were 
collected were in these hospital and transplant center.  
Selection criteria for PKD patients followed official di-
agnosis criteria,[11,12] including patient age (25–45 years old), 
the presence of borderline hypertension, and the number of 
bilateral renal cysts based on ultrasonography diagnosis. 
Selection criteria for non-PKD hypertensive (HTN) patients 
included borderline essential hypertension with no secon-
dary cause. Furthermore, they were selected to be age- and 
blood pressure- matched to the PKD patients following 
examination and clearance from consultant physicians. The 
exclusion criteria for HTN and PKD patients were preg-
nancy, lactation, diabetes mellitus, myocardial infarction, 
angina, renal transplantation, renal failure (or creatinine > 3 
mg/dL), dialysis, and arrhythmia (according to ECG report). 
None of the patients had taken any antihypertensive drugs at 
the time of the study. 
2.8  Clinical protocol 
The clinical study was a 3-way crossover and double- 
blind analysis designed to include two groups (Table 1). In 
each group, patients were further divided into three sub-
groups randomly. Each patient received treatments three 
times daily for 7 days. After a washout period of 10 days, 
each patient was randomly assigned to a different subgroup 
and received treatments three times daily for 7 days. After a 
second washout period of 10 days, each patient was put in  
Table 1.  Clinical study design.  
Group Sub-group Treatment 
A1 Placebo 
A2 50 mg levodopa 
Group A 
(HTN patients) 
A3 100 mg levodopa 
B1 Placebo 
B2 50 mg levodopa 
Group B 
(PKD patients) 
B3 100 mg levodopa 
A 3-way crossover and double-blind analysis was designed to include two 
groups, hypertensive groups without (HTN) or with polycystic kidney 
disease (PKD). In each group, patients were further divided into three sub-
groups randomly for a corresponding treatment. 
the last remaining subgroup to receive treatments three 
times daily for 7 days. For each treatment, patients received 
placebo, 50 mg or 100 mg levodopa capsules. A 20 mg of 
domperidone capsule was taken 30 min prior to all treat-
ments. Of note is that domperidone could block D2-like 
receptor activation by levodopa and thus prevent nausea.[13,14] 
The 10-day washout period was to ensure a complete re-
moval of levodopa from the body before the next treatment. 
As previously reported, the half-life of levodopa is 1–3 h 
and 7–9 h for domperidone.[15] 
We chose levodopa as the metabolic precursor of dopa-
mine in borderline hypertensive patients with or without 
PKD, because fenoldopam was not approved for use by the 
National Committee for Drug Selection at the Ministry of 
Health of Iraq. In our clinical study, domperidone was also 
used as a peripheral D2 dopaminergic antagonist for two 
reasons. First, it prevents some adverse effects such as nau-
sea induced by levodopa.[13,14] Second, by blocking D2 re-
ceptors, it potentiates activation of the D1 receptors, includ-
ing DR5, in the peripheral vascular system. From our clini-
cal data (Table 2), the baseline serum creatinine level was 
significantly higher in the PKD group than in the HTN 
group. This suggests a progressive deterioration in renal 
function in PKD, consistent with the imaging studies that 
indicate the presence of renal cysts in our patients.  
All physicians (Altaei QH, Alshimmari IK, Alsaidi MM 
and Khammas H) from different clinics or hospitals enrolled 
participations suitable to our study criteria independently, 
and they administered the interventions to the participants. 
The random allocation sequence of participants was gener-
ated by Kathem S and supervised by Ismail SH. Thus, nei-
ther physicians nor patients knew the subgroup classifica-
tions or treatment types. Because the steady state concentra-
tion of drug depends of its half-life, levodopa with a short 
half-life would reaches steady state within two days. As 
such, effects of levodopa on vasculatures should be apparent 
within a week of our study, which serves as an endpoint of 
our study. Blood pressure, heart rate and blood samples 
were taken before treatment (baseline), two hours after the 
first treatment, and two hours after the last dose on the sev-
enth day of the treatment period. There was no follow-up 
after the end of study period.  
2.9  Clinical measurements 
All measurements were taken after patients were in the 
sitting position for at least 10 min. Blood pressure and heart 
rate were measured by the physicians using mercury 
sphygmomanometer and Radial pulse rate, respectively. 
Blood samples (4–5 mL) were collected by venepuncture at 
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Figure 5.  Fenoldopam augmented cilia length, increased serum NO and improved blood pressure in Pkd1 mouse model (n = 3 for 
each experiment; at least 35 double-blind measurements for cilia length were made in each sample. (A): Baseline blood pressure was 
measured for at least 3 days in Pkd1flox/flox (wild-type) and Tie2Cre⋅Pkd1flox/flox (Pkd1) mice followed with intravenous administration of fen-
oldopam everyday at 1.5 mg/mL per minute for 30 min; (B): Serum NO was measured at day 3 before (control, C) and at day 9 after (fenol-
dopam, FD) administration of fenoldopam; (C): Cilia length was measured from the femoral arteries before C and after FD in Pkd1flox/flox 
(wild-type) and Tie2Cre⋅Pkd1flox/flox mice. *P < 0.05 from the baseline values before fenoldopam treatment. NO: nitric oxide. 
Levodopa, a dopaminergic agonist, was selected because it 
is clinically safe for convenient oral use; however, it func-
tions as a non-specific dopaminergic agonist for DR5 acti-
vation. Our double-blind study showed minimal effects of 
moderate dosages of levodopa (50 or 100 mg) on serum NO 
(Table 2). Of note, NO regulation in PKD is complicated 
partly because the increase in basal levels of superoxide and 
NO-induced peroxynitrite formation in smooth muscle 
cells.[17] It is therefore conceivable that the NO in our pa-
tients had reacted with superoxide to form peroxynitrite.  
Most importantly, the overall mean arterial pressure was 
significantly decreased in patients treated with 100 mg le-
vodopa in PKD patients (Figure 6C). Levodopa also showed 
similar effect on hypertensive-only group (Figure 7). This 
finding is consistent with our cell culture in vitro and mouse 
in vivo studies showing that activating DR5 can also 
increase cilia length and sensitivity to produce NO in nor-
mal wild-type control group. It is probable that our hyper-
tensive-only group had a constricted vascular tone that 
would also be beneficial with dopamine treatment.   
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Figure 6.  Serum levels of NO, ADMA and effects of levodopa on hypertensive-only and hypertensive-PKD patients. (A): Compared 
to HTN patients, baseline serum NO was significantly lower in hypertensive patients with PKD; (B): Compared to HTN patients, baseline 
serum ADMA was significantly higher in PKD patients; (C): Blood pressure was measured at baseline and 7 days after placebo or levodopa 
treatment. Levadopa is effective to improve mean arterial pressure in both HTN and PKD patients. *P < 0.05 between HTN and PKD groups 
(in A and B), or between different treatments and corresponding baseline groups (in C). ADMA: asymmetric dimethylarginine; HTN: hyper-
tensive-only; NO: nitric oxide; PKD: polycystic kidney disease. 
 
Figure 7.  Levodopa decreases the overall mean arterial 
pressure. Blood pressure was measured at baseline, 2-h and 7 days 
after placebo or levodopa treatment (placebo vs. 50 mg vs. 100 mg). 
Levadopa was effective to improve mean arterial pressure in both 
HTN and hypertensive-PKD patients. *P < 0.05 compared to cor-
responding baseline groups. HTN: hypertensive-only; PKD: poly-
cystic kidney disease. 
4  Discussion 
In the present study, our basic science studies indicated 
that activation of ciliary DR5 with DR5-specific agonist 
(fenoldopam) increases NO biosynthesis transiently. More 
importantly, DR5 activation increased cilia length, partially 
rescued mechanosensitivity of PKD endothelial cells to flu-
id-shear stress, and thereby decreased the overall mean arte-
rial pressure. In the clinical study, we showed that hyperten-
sive PKD patients had a significantly lower baseline level of 
NO compared to hypertensive-only patients. More impor-
tantly, modest dosage of levodopa at 50 mg or 100 mg de-
creased the mean arterial blood pressure in the PKD group. 
We also confirm that the baseline level of ADMA, an en-
dogenous inhibitor for eNOS and a marker for endothelial 
dysfunction, is significantly higher in the PKD group com-
pared to the hypertensive-only group. 
Consistent with the in vitro study, our in vivo data sug-
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gest that fenoldopam could extend the length of primary 
cilia and induce a greater NO production. These would ul-
timately decrease the overall mean arterial pressure in Pkd1 
mouse model. Of note is that fenoldopam at 1.5 mg/kg 
showed a trend of lower blood pressure in wild-type mice, 
albeit this decrease was not statistically significant. One 
possible explanation is that the baseline vascular tone in 
wild-type mice was already low. As a result, no significant 
effect of increasing NO on vasodilation was observed. It is 
worth mentioning that the baseline serum levels of NO were 
significantly lower in Pkd1 mice compared to wild-type. 
ADMA acting as a physiological inhibitor of NO bio-
synthesis has been used as a marker for endothelial function 
in the clinical setting.[18,19] Plasma ADMA levels are highly 
correlated with the severity of endothelial dysfunction, and 
high ADMA level further impairs blood flow and acceler-
ates atherogenesis through endothelial dysfunction.[20] Thus, 
our clinical data indicated that compared to the hyperten-
sive-only group, the PKD group had an abnormality in 
regulating NO biosynthesis. This is consistent with our pre-
vious study indicating that vascular-lining endothelia from 
patients with PKD are dysfunctional due to their non-re-
sponsiveness to flow-induce NO biosynthesis.[5] 
In particular, the mechanism of dopamine receptor, espe-
cially DR5, in blood pressure regulation still remains un-
known. Although it has been propose that peripheral dopa-
minergic activation increases renal blood flow,[21] we pro-
pose that this vasodilation effect of dopamine on renal ar-
teries acts by sensitizing primary cilia function. In our study, 
levodopa had a minimal effect on individual systolic or dia-
stolic blood pressure (Table 2). Without doubt, a more spe-
cific dopaminergic agonist for DR5 may be more suitable 
for therapeutic management of hypertensive PKD patients. 
Unfortunately, fenoldopam was not approved for use in our 
study. We did not seek for a higher dosage of levodopa due 
to the safety concerns in our patients. Nonetheless, our clini-
cal study sheds light on the possibility for cilia-targeted 
therapy in PKD patients and possibly in general hyperten-
sive patients. 
In summary, our results show that fenoldopam increased 
cilia length, which further enhanced the mechanosensory 
function of cilia in NO biosynthesis. Results from a less 
complex in vivo rodent system with endothelial cilia dys-
function support the idea that a DR5-cilia-NO axis plays an 
important role in regulating blood pressure in PKD. In a 
more complex clinical setting, dopaminergic receptor acti-
vation showed a potential therapeutic benefit on overall 
arterial blood pressure. Together, our studies serve as a 
proof of principle for targeted-clinical therapy on primary 
cilia as a novel mechanism to modulate the progression of a 
ciliopathy.  
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